Michael Gottlieb
Internal Medicine · Pasadena, CANPI 1871506808
Payments from drug & device makers
Across 731 payments — averaging $261.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$77K
- Merck$69K
- Gilead$17K
- Janssen Products, LP$11K
- Theratechnologies Inc.$5K
- EMD Serono, Inc.$5K
- plus $6K from 40 others
What the payments were for
- Consulting fees$34,54018%
- Speaking & faculty fees$133,40570%
- Travel & lodging$9,8275%
- Food & beverage$13,3227%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$191,258 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SerostimSomatropin | 24 | $466,917 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 56 | $224,874 |
| TivicayDolutegravir Sodium | 63 | $150,737 |
| CabenuvaCabotegravir/Rilpivirine | 12 | $71,777 |
| DovatoDolutegravir Sodium/Lamivudine | 23 | $66,124 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $65,449 |
| PifeltroDoravirine | 26 | $47,532 |
| IsentressRaltegravir Potassium | 16 | $31,159 |
| Darunavir | 11 | $10,119 |
| EliquisApixaban | 12 | $10,049 |
| VascepaIcosapent Ethyl | 11 | $3,813 |
| ValacyclovirValacyclovir Hcl | 49 | $3,555 |
| Varenicline Tartrate | 11 | $2,804 |
| Testosterone | 17 | $2,772 |
| Testosterone Cypionate | 26 | $1,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Serostim | $5,033 | $466,91724 claims |
| GileadBiktarvy, Descovy | $17,346 | $290,32386 claims |
| Viiv Healthcare CompanyTivicay, Cabenuva, Dovato | $77,416 | $288,63898 claims |
| MerckPifeltro, Isentress | $69,258 | $78,69142 claims |
| PfizerEliquis | $145 | $10,04912 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $34 | $14312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Pasadena
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.